Turbine

29/08/2025

We were excited to see Cate Lawrence’s article on TechEU about Turbine, diving into why so many biotech startups struggle to turn breakthroughs into commercial success - and how Turbine plans to beat the odds.

As Szabi, our CEO & Co-Founder, shared, many companies stumble because they underestimate four key challenges. At Turbine, we’ve spent the past decade tackling exactly those obstacles by building a platform that:
🤓Virtualizes biological experiments with AI to outscale any lab and run them faster, cheaper, and more translatable.
🤓Simulates billions of ideas while helping scientists focus on the right ones - not just more of them.
🤓Empowers pharma to prioritize drugs that will work, avoiding years of costly dead ends.
🤓Democratizes access to cutting-edge tool (to our Virtual Lab), putting a new way of working in every scientist’s hands.

👉 Full article:

The Budapest-based biotech has built the world’s first interpretable cell simulation platform — a “digital twin” of cellular systems that enables billions of in silico experiments.

12/08/2025

Early summer memory lane about the coolest moment from London Tech Week…

Back on June 10, at London Tech Week, Szabi, our Co-founder and CEO joined a powerful panel titled: “Digital Twins in Drug Development - Hype or Healthcare Revolution?”

He was in great company with Tony Ng, SVP & Head of Oncology Translational Research at GSK, diving deep into how digital twins are changing the way we understand - and treat - disease.

And then came the surprise plot twist: the session was moderated by none other than Jack Kreindler - investor, doctor, and someone who’s been part of Turbine’s story since the early days. Seeing him in action again (and leading the room like a true gym instructor) was the kind of full-circle moment we love.

Shoutout to for making room for honest, gritty science-talk at events like this. More of that, please.

07/08/2025

Turbine and our new MSD (Merck & Co., Inc., Rahway NJ, USA) partnership was featured in Forbes by journalist Alex Knapp in this week’s InnovationRx newsletter.

🐀As we say: We won’t replace animal testing, but we’ll definitely complement it. Our virtual disease models are second only to patients themselves.

Read the full piece here:

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ending drug testing on animals and more.

04/08/2025

✨Exciting partnership announcement!

We’re proud to share that Turbine is partnering with MSD (Merck & Co., Inc., Rahway NJ, USA) to unlock new possibilities in the fight against hard-to-treat cancers.

Using our AI-powered Simulated Cells™, we’ll create virtual tumor models that mimic patient biology, enabling the discovery of novel drug targets and therapies for cancers that are difficult to study in wet lab settings.

💥Check out the full press release below for more details: https://eu1.hubs.ly/H0m80kj0

Turbine, a leading developer of cell simulations with AI, today announced a research collaboration with MSD (the trade name of Merck & Co., Inc., Rahway NJ USA) to create simulations of cancer patient populations that remain difficult to treat and study in laboratory settings.

31/07/2025

🚀We believe simulating biology could be the next 'Genentech moment' for biopharma; one that fundamentally reshapes how the industry works.

We asked Klaus Hoeflich, PhD, Co-Founder and CEO at Versant NewCo; Co-Founder and Scientific Advisor at Nested Therapeutics; ex-Scientist at Genentech and long time member of Turbine’s Scientific Advisory Board, why he believes Turbine is one of the key players to make that moment happen.

💡His answer? Watch below.

24/07/2025

🚀Now is the time for Turbine to push towards virtualizing biological experiments.

We asked Gregory Vladimer, PhD, ex-VP of Translational Research at Exscientia and ex-CSO of Allcyte - a leader in bringing patient-derived data to the center of drug discovery.

"You’ve helped build and scale leading techbio platforms - why do you think now is the right moment for Turbine, and what makes it stand out?"

💡His answer? Watch below.

23/07/2025

We're thrilled to be showcasing our latest research at ISMB2025 in Liverpool!🇬🇧

Our team is presenting two cutting-edge posters that push the boundaries of computational biology:
🔬 "Computational Modeling of Immune Cell Phenotypes Enhances Prediction of Clinical Anti-Cancer Drug Response" - demonstrating how our platform predicts immune cell responses to enhance cancer drug discovery
📊 "Benchmarking Foundation Cell Models for Post-Perturbation RNA-seq Prediction" - revealing why simple baselines often outperform complex foundation models (spoiler: it's all about the data diversity!)

Both studies showcase how rigorous benchmarking and mechanistic understanding are paramount to driving drug discovery with AI. Our immune modeling work shows significant improvements in predicting clinical trial outcomes, while our benchmarking study exposes critical limitations in current evaluation approaches that the field needs to address.

Huge shoutout to Gema Sanz and Gerold Csendes for their outstanding work leading these projects! Want to dive deeper into both studies? Check them out at: https://eu1.hubs.ly/H0lXQ060

16/07/2025

Science doesn't work when forced. 🧪

Turbine CTO and Co-Founder Kristóf Szalay started experimenting with a new way to publish research - one that aims at fixing the gaps in the traditional scientific system:
▪️ Reward truth over outcomes or expectations
▪️ Discuss replications and dead ends
▪️ Share what works in practice (and what doesn't)

In our daily routine, no one is incentivized to produce a specific outcome. Our job is to find the truth. Dive into the full post below 👇
https://eu1.hubs.ly/H0lN8xh0

doing our part for stronger science

14/07/2025

🚀What makes Turbine’s approach stand out to someone who’s led one of pharma's most successful oncology portfolios?

We asked Andrew Pape, PhD, ex-VP Strategy, Oncology R&D at AstraZeneca and newly appointed SAB member at Turbine, about what convinced him that our platform matters for pharma.

💡His answer? Watch below.
We’re curious: what do you think will define the next generation of pre-clinical R&D?

10/07/2025

🚀Turbine is growing and so is our vision.

We're thrilled to welcome Andrew Pape, PhD and Gregory Vladimer, PhD to our Scientific Advisory Board. Their combined experience in oncology R&D strategy, translational research, and data-driven drug discovery will help us put virtual disease models in every scientist’s hands. With their insights, we're scaling a lab-in-the-loop future, where smarter experiments lead to better decision, and ultimately, better patient outcomes.

Learn more: https://eu1.hubs.ly/H0lGbGp0

Turbine, the company virtualizing experiments with AI to accelerate discovery and clinical decisions, today announced the addition of Andrew Pape, PhD and Gregory Vladimer, PhD to its Scientific Advisory Board.

09/07/2025

NIH’s policy shift underlines that to truly transform R&D, we must move from animal models, which too often fail to translate to the clinic, to toward human-representative models that better predict clinical outcomes.

At Turbine, we virtualize experiments with AI to accelerate discovery and clinical decisions. For 10 years, we’ve been obsessed with building virtual disease models that we believe are second only to the patient in predicting drug response.

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.

08/07/2025

Asia is becoming a global center of ADC innovation.

Our takeaways from World ADC Asia 2025 🚀
◾ Biotech leaders across China, South Korea, Japan, and Taiwan are launching first-in-class ADC platforms and pushing the boundaries of payload design.
◾ With 3,400+ ADC programs globally (70% preclinical), early-stage activity in Asia became a major growth engine.
◾ Deal flow is strong; Asia-based firms moved $1B+ into licensing deals and venture investments

Trends to watch 👀
◾ Bispecific and dual-payload ADCs are moving from concept to the clinic
◾ Novel mechanisms like degraders, immune modulators, and RNA-targeting payloads are gaining traction
◾ New targets (e.g. Claudin 6, IL1RAP) are opening doors to previously untreatable tumors

Turbine is already active in the region through our collaboration with Ono Pharmaceutical, and we’re aiming to expand our presence. Our improving ADC Payload Selector now goes beyond target expression, enabling:
✅ ADC positioning based on biological context
✅ Mechanistic interpretation at the node- and pathway-level
✅ Data generation and wet-lab validation support
✅ Custom payload evaluation using partner data inside a tailored virtual cell model

In a space that’s getting more complex and competitive by the day, we are helping our partners develop smarter and faster - using translatable models, second only to real patients.